£81.0M
The series C round was led by ORI Fund and will support clinical development of the company antibody pipeline.
K
Kymab
Kymab develops proprietary human monoclonal antibody therapeutics for serious diseases.
Cambridge, UK
£81.0MTotal raised
Kymab is a biopharmaceutical company based in Cambridge that develops human monoclonal antibody therapeutics to treat diseases such as HIV and malaria.